Scale-Down Model Development in ambr systems: An Industrial Perspective.

Area of Science:

• Biopharmaceutical Manufacturing
• Bioprocess Engineering
• Process Analytical Technology

Background:

• High-throughput (HT) technologies, including miniature bioreactors (MBRs), are integral to the biopharmaceutical industry.
• Traditionally used for pre-clinical screening, MBRs are gaining traction as scale-down models (SDMs) for late-stage clinical process characterization.

Purpose of the Study:

• To present a systematic approach for developing scale-down models (SDMs) using ambr 15 and 250 mL systems.
• To review recent advancements in qualifying MBRs as SDMs for biomanufacturing.

Main Methods:

• Utilizing ambr 15 and 250 mL systems for scale-down model development.
• Employing computational fluid dynamics (CFD) and in vitro analysis to match mass transfer and cellular stress.
• Implementing advanced risk assessment and statistical design of experiments (DoE).
• Combining uni- and multivariate data analysis techniques.

Main Results:

• ambr systems show promise as qualified SDMs for biomanufacturing.
• Improvements in process understanding, experimental design, and data analysis are key.
• The developed SDMs support more efficient, robust, and safe bioprocesses.

Conclusions:

• ambr systems can be effectively qualified as scale-down models (SDMs).
• Combinatorial improvements in process understanding, experimental design, and data analysis are crucial.
• These SDMs are anticipated to be applicable for future regulatory submissions, enhancing biomanufacturing efficiency and safety.